['hepatocellular carcinoma']
['sorafenib']

        Inclusion Criteria:

          -  Subjects must have confirmed diagnosis of unresectable hepatocellular carcinoma (HCC)
             categorized to stage C based on Barcelona Clinic Liver Cancer (BCLC) staging system
             with any of following criteria: 1) Lesion limited to a single lobe that is within the
             radiotherapy field, 2) Lesion not limited to a single lobe, but the lesion that is not
             within the radiotherapy field can be controlled by transarterial chemoembolization or
             radiofrequency ablation, 3) Presence of metastatic lesions that measure < 1.0 cm in
             the long axis, 4) The lesion can be accurately measured in at least one dimension as ≥
             1.0 cm

          -  Males or females aged at least 20 years and below 76 years

          -  Eastern Cooperative Oncology Group performance status (ECOG-PS) 0 or 1

          -  Adequate liver function, defined as: 1) Child-Pugh score ≤ 7, 2) Bilirubin ≤ 3.0 mg/dL

          -  Adequate bone marrow function, defined as: 1) Absolute neutrophil count (ANC) ≥ 1.5 ×
             109/L, 2) White blood cell count (WBC) ≥ 4.0 × 109/L, 3) Platelet count ≥ 60 × 109/L

          -  Adequate renal function, defined as serum creatinine < 2.0 mg/dL

          -  Subjects with hepatitis B virus (HBV)-related HCC must have adequately controlled HBV
             replication status

          -  Adequate blood coagulation factors, defined as international normalized ratio (INR) ≤
             2.3

          -  Provide written informed consent

          -  Willing and able to comply with all aspects of the protocol

        Exclusion Criteria:

          -  Significant liver function impairment, defined as bilirubin > 3.0 mg/dL or
             uncontrolled ascites

          -  Imaging findings for HCC corresponding to any of the following: 1) Diffuse HCC with >
             50% liver occupation, that is not adequate for external radiotherapy, 2) Presence of
             metastatic lesions that measure ≥ 1.0 cm in the long axis

          -  Uncontrolled significant active infection

          -  Presence of active malignancy (except for HCC)

          -  Females who are lactating or pregnant; females of childbearing potential who have not
             received pregnancy test or shown positive on pregnancy test

          -  Any medical or other condition that in the opinion of the investigator would preclude
             the subject's participation in a clinical study

          -  Major surgery within 4 weeks prior to enrollment
      